Search Results

You are looking at 1 - 3 of 3 items for :

  • "polymeric prodrugs" x
  • Refine by Access: All Content x
Clear All

Abstract  

Oxamniquine (OXA) is a schistosomicide agent that causes some adverse effects in central nervous system. Intending to improve OXA therapeutic properties, a polymeric prodrug was designed. Currently, there is an increasing interest of thermal analytical techniques in the pharmaceutical area, so differential thermal analysis (DTA) and thermogravimetry (TG) were carried out to evaluate the thermal behavior of OXA, polymethacrylic acid (PMA), [poly(methacrylic-co-oxamniquine methacrylate)acid] (PMOXA) and physical mixture (OXA+PMA). The thermoanalytical profile of the physical mixture showed characteristic events of the thermal decomposition of OXA and PMA. Distinctly, PMOXA DTA curve did not show an endothermic peak at 148.5C indicating that the drug was incorporated into the polymeric system. These results were corroborated by the IR spectroscopy and X-ray diffraction data.

Restricted access

Abstract  

Oxamniquine polymeric prodrug with potential antischistosomal activity was prepared using dextran T-70 as a carrier, which was analysed by 1HNMR, 13C NMR and IR spectroscopy. The formation of the oxamniquine salt was confirmed by thermogravimetric analysis (TG) and differential scanning calorimetry (DSC) which showed a different thermal behaviour when compared to the physical mixture.

Restricted access

-limiting cardiotoxicity, myelosuppression, and multi-drug resistance are its undesirable toxic effects that limit its clinical application [ 5 – 8 ]. In recent years, polymer pro-drugs have emerged as one of the most interesting fields for targeted cancer therapy due to

Open access